Catherine Abrial

2.5k citations

78 papers · 1.7k indexed · h-index 22

Impact in

Molecular Medicine top 2%
- Curcumin's Biomedical Applications
Cancer Research top 2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics

Papers in

Cancer Research 52
- Breast Cancer Treatment Studies 44
Oncology 62
- Cancer Treatment and Pharmacology 28
- HER2/EGFR in Cancer Research 17
- Cancer Risks and Factors 8
- Cancer Cells and Metastasis 7

Co-authors: Xavier Durando P. Chollet Marie‐Ange Mouret‐Reynier Frédérique Penault‐Llorca E. Planchat Émilie Thivat Marianne Leheurteur Fabrice Kwiatkowski
Journals: Journal of Clinical Oncology (10 papers)Oncology (7 papers)Cancer Research (5 papers)The Oncologist (5 papers)Clinical Breast Cancer (4 papers)
Partner nations: France United States Saudi Arabia

In The Last Decade

Catherine Abrial

74 papers receiving 1.7k citations

Peers

Countries citing papers authored by Catherine Abrial

Since Specialization

Citations

This map shows the geographic impact of Catherine Abrial's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Abrial with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Abrial more than expected).

Fields of papers citing papers by Catherine Abrial

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Abrial. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Abrial. The network helps show where Catherine Abrial may publish in the future.

Co-authors

The 25 scholars most cited alongside Catherine Abrial, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Catherine Abrial Line = papers co-authored together Catherine Abrial links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Predictive and Prognostic Factors in Epithelial Ovarian Cancer: A Review Indian Journal of Gynecologic Oncology ·A Shafiei Bafti, Gwendolyn M. Krueger, Ekram Saleh Mahmoud, T. Shimamura, А.М. Житенева, Ouyang Xiao, Catherine Abrial, Xavier Durando	2025	1
2	Comparison of the Predictive and Prognostic Capacities of Neutrophil, Lymphocyte and Platelet Counts and Tumor-infiltrating Lymphocytes in Triple-negative Breast Cancer: Preliminary Results of the PERCEPTION Study Anticancer Research ·A Shafiei Bafti, Ouyang Xiao, Myriam Kossaï, Yannick Bidet, Ioana Molnar, P. Scarpi, Frédérique Penault‐Llorca, Catherine Abrial, Xavier Durando, Nina Radosevic‐Robin	2024	2
3	RFID trial: localization of non-palpable breast lesions using radiofrequency identification tags or wire BMC Cancer ·貴裕大久保, D. Emrys Evans, 황지숙, T. Shimamura, Ioana Molnar, Catherine Abrial, Angeline Ginzac, Xavier Durando, Tanvi Singh	2023	4
4	20P Spatial analysis of residual tumor tissue provides new clues for post-neoadjuvant treatment approaches in triple-negative breast cancer ESMO Open ·Myriam Kossaï, Chris Holdgraf, 郝相俊, Ioana Molnar, Saniya, Catherine Abrial, Xavier Durando, Frédérique Penault‐Llorca, Yolanda García-Albuerne	2023	0
5	Treatment-Induced Cardiotoxicity in Breast Cancer: A Review of the Interest of Practicing a Physical Activity Oncology ·Angeline Ginzac, Ouyang Xiao, Émilie Gadéa, Catherine Abrial, Ioana Molnar, Romain Trésorier, Martine Duclos, Émilie Thivat, Xavier Durando	2019	27
6	Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy Annals of Oncology ·Nina Radosevic‐Robin, Emiliano Cocco, Helen Won, M Berger, Maud Privat, Catherine Abrial, Nnaji Ezechimelu, L. Gołaski	2017	1
7	A Retrospective Study on the Onset of Menopause after Chemotherapy: Analysis of Data Extracted from the Jean Perrin Comprehensive Cancer Center Database Concerning 345 Young Breast Cancer Patients Diagnosed between 1994 and 2012 Oncology ·Raphael Neves, Marie‐Ange Mouret‐Reynier, Fabrice Kwiatkowski, K. Pitchumani, Pauline Herviou, Daniel L. Toth, Catherine Abrial, Frédérique Penault‐Llorca	2017	6
8	The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study Oncology ·Hakim Mahammedi, E. Planchat, Daniel L. Toth, Xavier Durando, Hervé Curé, Laurent Guy, Χρυσούλα Δημοπούλου, H. Jeffrey Kim, N Abad, Mathilde Bayet‐Robert, Émilie Gadéa, Catherine Abrial, Émilie Thivat, P. Chollet, Jean‐Christophe Eymard	2016	112
9	Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? Critical Reviews in Oncology/Hematology ·С.Н. Пятакова, Nasséra Chalabi, Catherine Abrial, Nina Radosevic‐Robin, Xavier Durando, Marie‐Ange Mouret‐Reynier, Jeffery Y. Tien, Sharif Kullab, 冀秋娣, P. Chollet, Frédérique Penault‐Llorca, Jean‐Marc Nabholtz	2015	68
10	Is It Important to Adapt Neoadjuvant Chemotherapy to the Visible Clinical Response? An Open Randomized Phase II Study Comparing Response-Guided and Standard Treatments in HER2-Negative Operable Breast Cancer The Oncologist ·С.Н. Пятакова, Marie‐Ange Mouret‐Reynier, Aude-Marie Savoye, Catherine Abrial, Fabrice Kwiatkowski, Christian Garbar, Pascale Dubray‐Longeras, Jean‐Christophe Eymard, A. Erra, Χρυσούλα Δημοπούλου, Frédérique Penault‐Llorca, P. Chollet, Hervé Curé	2015	2
11	BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib Scientific Reports ·G.D. Li, Gajare Vikas, Emmanuelle Mounetou, Corinne Aubel, Fabrice Kwiatkowski, Catherine Abrial, Hitomu Matsui, Frédérique Penault‐Llorca, Mahchid Bamdad	2015	33
12	The role of tomosynthesis in breast cancer staging in 75 patients Diagnostic and Interventional Imaging ·Salina Som, Fabrice Kwiatkowski, Catherine Abrial, F. C. BURKITT, Peri Gretton, 祝富友, A. V. Shabunin, Lide Guo	2014	24
13	Late lines of treatment benefit survival in metastatic breast cancer in current practice? The Breast ·E. Planchat, Catherine Abrial, Émilie Thivat, Marie‐Ange Mouret‐Reynier, Fabrice Kwiatkowski, Christophe Pomel, С.Н. Пятакова, P. Chollet, Jean‐Marc Nabholtz, Xavier Durando	2011	19
14	Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse BMC Cancer ·Émilie Thivat, Pijush Meher, Olivier Lapirot, Catherine Abrial, Pierre Gimbergues, Émilie Gadéa, E. Planchat, Fabrice Kwiatkowski, Marie Ange Mouret‐Reynier, P. Chollet, Xavier Durando	2010	92
15	Clinicopathological Factors and Nomograms Predicting Nonsentinel Lymph Node Metastases After Neoadjuvant Chemotherapy in Breast Cancer Patients Annals of Surgical Oncology ·Pierre Gimbergues, Catherine Abrial, Xavier Durando, G. Le Bouëdec, F. Cachin, Frédérique Penault‐Llorca, M-A Mouret-Reynier, Fabrice Kwiatkowski, J. Maublant, Andréï Tchirkov, J Dauplat	2009	7
16	Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Is Accurate in Breast Cancer Patients with a Clinically Negative Axillary Nodal Status at Presentation Annals of Surgical Oncology ·Pierre Gimbergues, Catherine Abrial, Xavier Durando, G. Le Bouëdec, F. Cachin, Frédérique Penault‐Llorca, M-A Mouret-Reynier, Fabrice Kwiatkowski, J. Maublant, Andréï Tchirkov, J Dauplat	2008	68
17	Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer Human Pathology ·Frédérique Penault‐Llorca, Catherine Abrial, E. Sendagorta, Anne Cayre, Marie‐Ange Mouret‐Reynier, Marianne Leheurteur, Xavier Durando, J.L. Achard, Pierre Gimbergues, P. Chollet	2008	51
18	Achieving Higher Pathological Complete Response Rates in HER-2–Positive Patients With Induction Chemotherapy Without Trastuzumab in Operable Breast Cancer The Oncologist ·Frédérique Penault‐Llorca, Catherine Abrial, Marie‐Ange Mouret‐Reynier, E. Sendagorta, Xavier Durando, Marianne Leheurteur, Pierre Gimbergues, J. Tortochaux, Hervé Curé, P. Chollet	2007	7
19	Mammalian Target of Rapamycin Inhibitors in Combination with Letrozole in Breast Cancer Clinical Breast Cancer ·P. Chollet, Catherine Abrial, Ilyas Akarkach, Marie‐Ange Mouret‐Reynier, Marianne Leheurteur, Xavier Durando, Hervé Curé	2006	39
20	Stress, cancer et rythme circadien de la mélatonine Pathologie Biologie ·Fabrice Kwiatkowski, Catherine Abrial, Frédéric Gachon, Wei Gao, H. Curé, P. Chollet	2005	8

About Catherine Abrial

Catherine Abrial is a scholar working on Cancer Research, Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Endocrine and Autonomic Systems, having authored 78 papers that have together received 1.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (44 papers), Cancer Treatment and Pharmacology (28 papers), HER2/EGFR in Cancer Research (17 papers), Breast Lesions and Carcinomas (12 papers), Advanced Breast Cancer Therapies (11 papers), Cancer Risks and Factors (8 papers), Estrogen and related hormone effects (8 papers) and Cancer Cells and Metastasis (7 papers). The work is most often cited by research in Molecular Medicine (284 citations), Cancer Research (722 citations), Oncology (772 citations), Pathology and Forensic Medicine (341 citations) and Pulmonary and Respiratory Medicine (254 citations). Catherine Abrial has collaborated with scholars based in France, United States and Saudi Arabia. Frequent co-authors include Xavier Durando, P. Chollet, Marie‐Ange Mouret‐Reynier, Frédérique Penault‐Llorca, E. Planchat, Émilie Thivat, Marianne Leheurteur, Fabrice Kwiatkowski, Pierre Gimbergues and Mathilde Bayet‐Robert. Their work appears in journals such as Journal of Clinical Oncology, Oncology, Cancer Research, The Oncologist and Clinical Breast Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact